A mock clinical pathway development simulation was conducted to make transparent the process of developing consensus-driven, evidence-based clinical pathways in oncology. 
George Dahlman responds to a viewpoint on chemotherapy drug shortages by detailing policy measures that have been put in place to help address this issue. 
Yoram Unguru, MD, MS, MA addresses the pervasive problem of drug shortages in cancer care and what is being done to resolve the issue. 
The authors detail the development of a set of decision support rules for application within a major academic medical center and across its affiliated community satellite sites.
Authors examine different cost control levers the government could use to affect drug pricing and have an impact on treatments selected within clinical pathways. 
Winston Wong, PharmD, explains how the recent policy statement released by the American Society of Clinical Oncology represents a significant step forward for clinical pathways as a whole.